LNP–mRNA drug products are produced by mixing the nucleic acid drug substance with various lipid components, such as phospholipids, cholesterol, PEG–lipids and ionizable lipids, resulting in a ...
The primary components of LNP–RNA are ionizable lipids, cholesterol, PEGylated lipids, and phospholipids, which together form the nanoparticle, along with the active pharmaceutical ingredient, RNA.
Microfluidics technologies offer a clear pathway to ensure the precise convergence of lipids and mRNA to produce nanoparticles of consistent size and structure, generating uniform and monodisperse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback